bioAffinity Technologies Inc (BIAF) Actualités

Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis

Study by BAMC’s Michael Morris, M.D., and VA’s Sheila Habib, M.D., evaluated potential economic impact of CyPath® Lung for the early detection of...

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO

Edwards held CFO position at bioAffinity for nine years, leading Company through successful IPO bioAffinity Technologies, Inc. (Nasdaq: BIAF;...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales

Q2 CyPath® Lung test sales up 217% over Q1 2024 Expanded CyPath® Lung test sales to physicians in California and Ohio; now receiving orders from...

Form D - Notice of Exempt Offering of Securities

Form D - Notice of Exempt Offering of Securities

WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant...

bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW) announced today that pursuant to warrant exercise agreements dated Aug. 2, 2024, three...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant...